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Aspergillus fumigatus triazole resistance is an emerging concern for treating chronically
infected/colonized patients. This study sought to evaluate the performance of PCR
assays to detect Aspergillus fungi together with azole resistance in sputum samples
from cystic fibrosis (CF) patients. In total, 119 sputum samples from 87 CF patients
were prospectively processed for Aspergillus detection by means of mycological culture
and four qPCR assays, 2 in-house methods and two commercial multiplex real-time
PCR assays simultaneously detecting Aspergillus and the most relevant cyp51A gene
mutations (MycoGENIE R© and AsperGenius R©). Azole susceptibility of A. fumigatus isolates
was assessed using Etest R© method and cyp51A gene mutation were characterized by
sequencing. The overall rate of Aspergillus detection with the four qPCR assays ranged
from 47.9 to 57.1%, contrasting with 42/119 (35.3%) positive cultures with A. fumigatus.
The high sensitivity of PCR on sputum could then contribute to more effective grading of
Aspergillus disease in CF patients. Five out of 41 isolated strains (12.2%) exhibited azole-
resistant MIC patterns, three of which harbored cyp51A mutations and only 1/3 with
the sequence TR34/L98H. Combined with culture, PCR assay achieved high sensitivity
Aspergillus screening in CF samples. However, cyp51A targeting was only moderately
effective for azole resistance monitoring, while Aspergillus resistance remains of great
concern.
Keywords: Aspergillus, aspergillosis, cystic fibrosis, quantitative real-time PCR, azole resistance, sputum
INTRODUCTION
Aspergillus fumigatus is responsible for severe asthma or allergic bronchopulmonary aspergillosis
(ABPA) in up to 15% of cystic fibrosis (CF) patients (Stevens et al., 2003; Pihet et al., 2009), though
the significance of its detection is often questioned when there are no accompanying clinical signs.
A. fumigatus is usually susceptible to triazole antifungal drugs (with the exception of fluconazole),
which have proved beneficial in treating chronic pulmonary aspergillosis (CPA). During ABPA and
chronic colonization, however, their use is still controversial (Stevens et al., 2003; Pihet et al., 2009).
Frontiers in Microbiology | www.frontiersin.org 1 March 2018 | Volume 9 | Article 531
fmicb-09-00531 March 24, 2018 Time: 14:13 # 2
Guegan et al. Aspergillus PCR in Cystic Fibrosis
Over the last decade, A. fumigatus resistant isolates to triazole
have been increasingly reported, and proven associated with a
markedly higher mortality rate (van der Linden et al., 2011).
This decreased susceptibility is primarily due to mutations
in the cyp51A gene encoding lanosterol 14α-demethylase, the
enzyme involved in ergosterol biosynthesis (Mellado et al.,
2001; Alcazar-Fuoli and Mellado, 2013). While TR34/L98H and
TR46/Y121F/T289A alterations account for the majority of azole
resistance cases, a large diversity of cyp51A mutations has also
been associated with resistance (Verweij et al., 2016). Mutations
have been thought to arise during prolonged antifungal therapy
or prophylaxis in individual patients, yet a number of these
mutated strains were cultured from patients with no previous
azole exposure. Recent data suggest that the proliferating
resistance is also caused by intensive use of azole fungicides
in agriculture (Verweij et al., 2016). In France, the prevalence
of resistant A. fumigatus strains grown from sputum samples
of CF patients is particularly high, ranging from 4.6 to 10.6%
(Burgel et al., 2012; Morio et al., 2012). On the other hand, the
current prevalence of triazole resistance in immunocompromised
patients with invasive aspergillosis (IA) still remains low,
estimated at ≤1% in France (Alanio et al., 2011; Guegan et al.,
2018).
In vitro antifungal susceptibility testing is thus essential for
patient management. In routine practice, the detection of azole
resistance is primarily based on the in vitro determination
of minimum inhibitory concentration (MIC) from isolates.
However, the data on A. fumigatus resistance are scarce as
susceptibility testing is not always routinely performed and
sputum culture lacks sensitivity. To overcome these limitations
in resistance screening, molecular methods have recently been
developed to detect A. fumigatus cyp51A gene mutations,
primarily in clinical specimens. Several nested PCR assays (van
der Linden et al., 2010; Denning et al., 2011; Spiess et al., 2012,
2014) and commercial kits have previously been used, such
as Aspergenius R© (Chong et al., 2015; White et al., 2015) and
Mycogenie R© (Dannaoui et al., 2017) targeting both Aspergillus
and key cyp51A alterations associated with azole resistance,
though they have yet to be evaluated in field studies, particularly
involving patients with chronic infection.
In this study, we prospectively investigated the prevalence of
Aspergillus and the triazole resistance of A. fumigatus in sputum
samples from CF patients using both phenotypic and molecular
approaches. The efficacy of two commercial multiplex PCR
assays AsperGenius R© (PathoNostics, Maastricht, Netherlands)
and Mycogenie R© (Ademtech, Pessac, France) were compared
with two real-time in-house Aspergillus assays as well as cultures.
The ability of these PCR assays to detectAspergillus and resistance
markers was compared with culture-based susceptibility testing
and subsequent cyp51A gene sequencing.
MATERIALS AND METHODS
Population
Over a 6-month period, (December 2015–May 2016), all
expectorated sputum samples collected from CF patients as part
of their routine quarterly follow-up at the Centre de Ressources
et de Compétences de la Mucoviscidose at Rennes University
Hospital (France) were included. The samples were processed for
all methods each time the minimum sample volume (≥1 ml) was
available.
Sputum Culture
On reception, 1–2 mL of sputum were digested with 1X Digest-
EUR R©, Eurobio (ratio: 1:1), and homogenized for 30 min at room
temperature. Samples were divided into two aliquots to perform
fungal culture and PCR assays, respectively.
For the cultures, 100 µL of pellets were inoculated in two
plates of fungal media (Sabouraud dextrose agar supplemented
with 0.5% chloramphenicol). One was incubated at 30◦C and the
other at 37◦C for 7 days (Borman et al., 2010). Mold types isolated
from the cultures were identified by microscope.
DNA Extraction From Sputum Samples
We extracted 1mL of digested sputum for centrifugation, and
DNA was extracted from a 200 µL pellet using the QIAamp R©
DNA Mini Kit (Qiagen) following overnight incubation with
proteinase K, according to the manufacturer’s instructions. As
an extraction control, 10 µL of viral DNA (DiaControlDNA,
Diagenode) were added. Elution was performed in 100 µL, and
the extracted DNA was stored at−20◦C until PCR testing.
Susceptibility Testing
Each A. fumigatus isolate recovered from Sabouraud slants was
tested as an individual isolate using itraconazole (ITC) and
voriconazole (VRC) Etest R© strips (Biomérieux, Marcy-L’Etoile,
France). MICs were determined following 48 h incubation at
37◦C. Posaconazole (POS) susceptibility was also tested using
Etest R© method, only for strains with decreased susceptibility
to ITC or VRC. Strains with MIC >2 mg/L for ITC and
VRC, and >0.25 mg/L for POS, were considered resistant,
according to recent EUCAST breakpoints for fungi (European
Committee on Antimicrobial Susceptibility Testing [EUCAST],
2017).
In-House Aspergillus PCR Assays
Sputum DNA extracts were tested using two real-time “in-house”
PCR assays for Aspergillus detection.
The first PCR assay (“Af-mito”) amplified a 196 bp-
sequence of A. fumigatus mitochondrial gene, as previously
described (F: GAAAGGTCAGGTGTTCGAGTCA; R: CATC
ATGAGTGGTCCGCTTTAC; 5′FAM and 3′TAMRA-labeled
probe 5′-ATCCCTAAACCCGCAACCAAAGGC) (Bretagne
et al., 1995).
The second PCR assay (“28S”) targeted a 67 bp-fragment
of the A. fumigatus 28S rRNA gene, employing the primers
and probe used by Challier et al. (2004) (28S-466: CTCG
GAATGTATCACCTCTCGG; 28S-533: TCCTCGGTCCAGG
CAGG; 28S-490: FAM-TGTCTTATAGCCGAGGGTGCAATGC
G-TAMRA).
Each amplification was performed in a 25 µL final volume
containing 1X TaqMan R© Universal PCR MasterMix, 0.5 µM
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of each primer, 0.2 µM of probe, 2.5 µL of mix for internal
control amplification (DiaControlDNA, Diagenode), and 5 µL of
sampled DNA.
Amplification was performed in the following thermal
conditions: 2 min at 50◦C, 10 min at 95◦C, and 45 cycles of 15 s
at 95◦C, then 1 min at 60◦C, all on a StepOne Plus R© instrument
(Applied Biosystems).
Commercial Aspergillus PCR Assays
Sputum specimens were analyzed by means of two commercial
multiplex real-time PCR assays simultaneously detecting
Aspergillus and the most relevant cyp51A gene mutations.
MycoGENIE R© (AdemTech, Pessac, France) is a quadruplex
real-time PCR assay which targets A. fumigatus (28SrRNA
multicopy gene) in the TR34 and L98H regions of the single-copy
cyp51A gene, including an internal control to monitor for sample
inhibition. Amplification was performed over 45 cycles, using
an LC480 PCR device (Roche, Meylan, France). When the
A. fumigatus target was negative and the Ct value >35 for
IC amplification, or when results contrasted with those of the
in-house PCRs, the samples were retested, diluted to 1:10, 1:20,
and 1:50.
AsperGenius R© assay (PathoNostics, Maastricht, Netherlands)
provides two different real-time quadruplex amplification
mixtures, one for the detection of Aspergillus species, and
the other one for identifying prevalent resistance mutations.
The species multiplex assay enables specific detection of the
A. fumigatus complex (Af), A. terreus, and Aspergillus sp.
(Asp sp.), by targeting the 28S rRNA multicopy gene. Samples
were retested diluted to 1:10 if the internal control Ct was
>36. The resistance multiplex assay targets the single-copy
cyp51A gene of A. fumigatus, and can detect the TR34, L98H,
Y121F, and T289A regions. Distinction between wild-type and
mutant A. fumigatus strains was performed by melting curve
analysis. The differences in fusion temperatures necessary to
assign resistance were interpreted following the manufacturer’s
instructions.
Amplification was performed over 45 cycles, according to the
manufacturer’s instructions, on a LightCycler R© 480 instrument
(Roche). Analysis was performed on the LightCycler R© 480
software, using the second derivative function. The horizontal
threshold was fixed above background noise and a positive
result was defined by a signal detection with a Ct value <45
cycles.
DNA Extraction From Resistant
A. fumigatus Strains
DNA was extracted from A. fumigatus cultures a minimum
of 4 days old. A conidial suspension was created in MagNA R©
Pure Bacteria Lysis Buffer (Roche) and transferred to a MagNa R©
Lyser Green Beads tube (Roche) for homogenization with
the MagNa R© Lyser Instrument (Roche). We then extracted
400 µL of supernatant using the MagNa R© Pure Compact
Nucleic Acid Isolation Kit and a MagNa R© Pure Extraction
Instrument (Roche Diagnostics), according to the manufacturer’s
instructions.
Molecular Identification of Resistant
Strains
Identification ofA. fumigatus isolates with ITC MIC>2 mg/L was
further confirmed by beta-tubulin gene sequencing.
PCR amplification was performed using Bt2a and Bt2b
primers (Glass and Donaldson, 1995). Amplification reaction and
subsequent sequencing were performed as previously described
(Comacle et al., 2016). Sequencing was performed using an
ABI PRISM R© 3130 Genetic Analyzer (Applied Biosystems).
Bidirectional sequences were analyzed using Seqscape R© software
v.2.5 and assessed within the GenBank public database using
the BLAST Search program for comparison and species
identification.
Cyp51A Gene Typing
The whole cyp51A gene and its promoter were sequenced in
both strands from all A. fumigatus strains with elevated MIC
values, using five sets of primers: PA5 and PA7 (Mellado et al.,
2001), AF306F and AF855R, AF766F and AF1330R, AF1179F
and AF1709R, and AF1426F and AF2025R (Alanio et al., 2011).
The PCR mixture contained 5 µL of DNA extract and 20 µL
of mix composed of 0.625 U of GoTaq R© Hot Start Polymerase
(Promega), 1x Colorless GoTaq R©Flexi Buffer (Promega), 2 mM of
MgCl2 (Promega), 0.8mM of dNTP mix (Eurobio), and 0.2 µM
of each primer. The amplification program consisted of 5 min at
94◦C, 30 cycles of 30 s at 94◦C, 30 s at 58◦C, and 1 min at 72◦C,
followed by a final step of 10 min at 72◦C.
Following purification and sequencing as described above,
sequences of resistant strains were compared to the wild-type
A. fumigatus sequence CM 237 (GenBank accession number
AF338659), at http://blast.ncbi.nlm.nih.gov/Blast.cgi.
Statistical Analysis
Data analysis was performed using GraphPad PRISM R© v.5.02
software. For continuous variables, the Mann–Whitney test was
used. A p-value of 0.05 was considered statistically significant.
RESULTS
Study Population
One hundred and nineteen specimens were collected in the
context of routine clinical follow-up from 87 CF patients (sex
ratio: 1.1), aged 4–59 years old (mean age: 26 ± 13 years), and
included for both culture and PCR assays. Of the 87 patients, 37
(42.5%) were receiving triazole therapy at the time of sampling,
specifically itraconazole (n = 25), posaconazole (n = 11), or
voriconazole (n = 1).
Detection of Aspergillus in Sputum
Samples
As depicted in Table 1, A. fumigatus grew in 42 of the 119 sputum
samples (35.3%), corresponding to 33 distinct patients. The two
in-house Af-mito and 28S PCRs were positive in 65 (54.6%) and
68 samples (57.1%), respectively. Only 37 and 38 of the 42 sputum
samples grown with A. fumigatus yielded positive PCR results
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TABLE 1 | Aspergillus PCR results according to sputum culture results (n = 119).
Culture results Positive Aspergillus PCR assay results n (%)
Af mito PCR 28S PCR Mycogenie R© PCR Aspergenius R© Af PCR Aspergenius R© Asp sp. PCR
All (n = 119) 65 (54.6) 68 (57.1) 64 (53.8) 57 (47.9) 64 (53.8)
Positive culture for Aspergillus
A. fumigatus (n = 42) 37 (88.1) 38 (90.5) 31 (73.8) 33 (78.6) 35 (83.3)
Non-fumigatus Aspergillus speciesa (n = 5) 2b (40.0) 2b (40.0) 2b (40.0) 2b (40.0) 3b,c (60.0)
Positive culture for other moldsd (n = 19) 2e (10.5) 3e (15.8) 3e (15.8) 1e (5.3) 2f (10.5)
Negative culture g (n = 55) 26 (47.3) 27 (49.1) 30 (53.6) 23 (41.8) 26 (43.3)
aA. nidulans (n = 1), A. versicolor (n = 1), Aspergillus sp. (n = 1), A. terreus (n = 1), A. flavus (n = 1). bSamples grown simultaneously with A. fumigatus and flavus (n = 1),
A. fumigatus and A. terreus (n = 1). cA. nidulans (n = 1). dScedosporium sp. (n = 6); Penicillium sp. (n = 8); Rasamsonia argillacea (n = 2); dematiaceous molds (n = 2);
unidentified mold (n = 1). eAll were Scedosporium sp.. fScedosporium sp. (n = 1), Penicillium (n = 1) gYeasts were not taken into account. PCR, polymerase chain reaction.
with Af-mito and 28S PCR, respectively. Roughly similar results
were recorded with the two commercial PCRs (Mycogenie R© and
Aspergenius R©), which amplified 64 (53.8%) and 57 (47.9%) of the
total 119 samples, respectively.
Of note, the use of internal control for PCR inhibitors
monitoring showed the presence of inhibitors to be prevalent in
sputum samples. For in house-PCRs, 28 out of 119 (20%) samples
yielded a positive signal for Aspergillus detection after dilutions
(up to 1:50).
Interestingly, all PCRs detected A. fumigatus in a large number
of samples that were negative in culture. As many as 41.8% to
53.6% of the 55 negative culture samples were, in fact, positive
with at least one of the four PCRs. Mycogenie R© achieved the
highest sensitivity in these samples, detecting 30/55 positive
specimens (53.6%), whereas the AsperGenius R© PCR targeting
A. fumigatus (Af) offered the lowest sensitivity (23/55, 41.8%).
The AsperGenius R© Asp sp. assay was positive in 26/55 negative
culture samples (43.3%), two of which tested positive exclusively
for this target, suggesting that non-Aspergillus DNA was present
in these samples.
None of the three sputum specimens grown with only
non-A. fumigatus species yielded positive results with any of
the four PCRs specifically targeting A. fumigatus. Conversely,
Aspergenius R© Asp sp. correctly detected A. nidulans, yet was
negative for the sample grown with A. versicolor. Finally,
as observed previously by our team, all the PCRs yielded
cross-reaction, with three out of six specimens detected as
positive for Scedosporium (Guegan et al., 2018).
Resistance Screening Using Commercial
PCR Assays
As shown in Table 2, no cyp51A gene alterations were detected
by Mycogenie R© and Aspergenius R© assay in the 57 and 64
sputum samples positive for A. fumigatus, respectively. However,
Aspergenius R© assay correctly amplified the four regions of
the cyp51A gene in only 20 of the 57 assessable specimens
(35%). Amplification success was variable and depended on
the cyp51A target, with detection rates ranging from 38.6%
(L98H region) to 56.1% (T289A region) (Table 2). This finding
was probably linked to the low fungal burden in samples with
incomplete cyp51A typing, as shown by the mean Ct values of
Af target, which were significantly higher in samples with failed
amplification compared to others (32.7 ± 1.6 vs. 34.1 ± 1.6,
p = 0.005).
Resistance Screening Using MIC
Determination
We were able to assess susceptibility to triazole drugs for 41/42
A. fumigatus isolates. As presented in Figure 1, five isolates
presented a resistance profile (12.2%) with high ITC MIC
(≥32 mg/L). Of these five, collected from five distinct patients,
three displayed cross-resistance to VRC, with high MICs ranging
from 8 to >32 mg/L. Susceptibility to POS was also reduced in
four of the five strains (MICs from 4 to >32 mg/L).
Cyp51A Gene Sequencing of Resistant
A. fumigatus Isolates and Occurrence
During Patient Follow Up
The whole cyp51A gene of the five resistant isolates was further
sequenced to identify the mechanism responsible for resistance.
Three of the five displayed cyp51A gene alterations (Table 3).
One L98H mutation (associated with a 34 bp tandem repeat
in the promoter) was found in a pan-azole-resistant isolate.
Surprisingly, the sputum sample from which this strain was
cultured did not yield a detection of cyp51A mutation with
any PCR assay (Mycogenie R©, Aspergenius R©). M220K and G54R
mutations were both observed in strains with ITC and POS
combined resistance.
The characteristics of patients colonized with resistant strains
are depicted in Figure 2. All five had been receiving long-
term itraconazole therapy for periods ranging from 11 months
(Patient 1) to over 10 years (Patient 4) prior to sampling. No
correlation was found between patient age or duration of triazole
exposure and cyp51A genotype.
DISCUSSION
The burden of Aspergillus infections and sensitization is high
among fungal diseases, particularly in the context of chronic
pulmonary diseases (Gangneux et al., 2016). The emergence
of triazole resistance in A. fumigatus has fuelled interest in
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TABLE 2 | Detection of cyp51A mutation using Mycogenie R© and Aspergenius R© assays.
PCR assay Number of positive samples (%) for
A. fumigatus TR34 L98H Y121F T289A
AsperGenius R© Target amplificationa 57 (47.9) 25/57 (43.9) 22/57 (38.6) 30/57 (52.6) 32/57 (56.1)
Detection of mutated alleleb NA 0/25 0/21 0/30 0/32
Mycogenie R© Detection of mutated allele 64 (53.8) 0/64 0/64 NA NA
NA, not applicable. aSuccessful detection of regions carrying targeted mutations. bMutated cyp51A allele detection achieved by determining melting temperature values
from TR34, L98H, Y121F, and T289A region amplicons.
FIGURE 1 | Distribution of itraconazole (ITC) and voriconazole (VRC) minimum inhibitory concentrations (MICs) of 41 Aspergillus fumigatus strains using Etest R©.
molecular screening of clinical specimens. Here, we investigated
prospectively whether using two commercial PCR assays was
effective in (i) detecting Aspergillus in sputum samples from CF
patients compared to culture or in-house PCRs, and (ii) in typing
azole resistance.
Aspergillus fumigatus was the most frequent fungus isolated
from CF sputum, with 35.3% of samples testing positive. PCR
offered much higher sensitivity than culture, with over 40% of
TABLE 3 | Minimum inhibitory concentration (MIC) and cyp51A sequencing of
azole-resistant isolates.
Patient n◦ cyp51a mutation (typing) MIC Etest R© (mg/L)
Nucleotide
sequence
Amino acid
sequence
VRC ITC POS
1 None None 16 32 0.094
2 t293a TR34/L98H >32 >32 >32
3 t659a M220K 1.5 >32 >32
4 g160a G54R 0.25 >32 >32
5 None None 8 32 4
MIC, minimum inhibitory concentration; VRC, voriconazole; ITC, itraconazole; POS,
posaconazole.
negative cultures yielding positive results with at least one PCR
assay. There is very little data on PCR efficacy in CF sputum
analyses in the literature, and our results reinforced the findings
of a previous study that revealed considerable discrepancies
between culture and PCR sensitivity (33% vs. 73%, respectively)
(Baxter et al., 2011). We performed a standardized sputum
homogenization, as this process has been shown to be crucial
for these analyses (Baxter et al., 2011). The viscous nature and
complex matrix of CF sputum can be responsible for inhibition
and impaired detection. We thus introduced internal checks to
monitor sample inhibition and systematically performed sample
dilutions for in-house PCRs to minimize this phenomenon.
More than 20% were found to contain PCR inhibitors. Exposure
to antifungals may also contribute to limited performances
of culturing but also molecular detection of Aspergillus. In
the context of invasive aspergillosis, we previously showed the
worth of molecular detection of Aspergillus in intensive care
unit patients compared to patients that benefit from antifungal
prophylaxis in hematology units (Guegan et al., 2018).
Scedosporium is usually considered the second most prevalent
filamentous fungus in CF. In our study, we recorded a significant
incidence of Scedosporium isolates (6/119), producing three
positive PCR results. These results question an apparent lack of
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FIGURE 2 | Date of treatment onset and time frame of sample collection over the study period. Isolates susceptible to azole are represented by open triangles,
isolates resistant to at least one azole are represented by black triangles. Respective MIC values (mg/L) are indicated. MIC, minimum inhibitory concentration; ITC,
itraconazole; VRC, voriconazole; ND, not determined; F, female; M, male; /n, age in years. Susceptibility testing was performed only from 09/2015.
specificity of the Aspergillus PCR assay regarding Scedosporium
species. Three isolates were sequenced using the ITS1-5.8S-ITS2
gene. No species relationship was confirmed, as all strains were
identified as part of Scedosporium apiospermum complex (data
not shown).
While some studies have identified associations between
Aspergillus isolation in sputum samples and the risk of pulmonary
exacerbations or deteriorating respiratory function (Amin et al.,
2010), the clinical relevance of PCRs in these specimens has
not yet been assessed. The question remains, for example, of
whether DNA fungal detection is associated with respiratory
disease or is only a marker of colonization (Jones et al., 2014). In
our cohort, the detection of serological markers was completed
within a 3-month period surrounding sputum sampling for 26
of the 27 patients producing positive PCRs but negative cultures.
Aspergillus antibodies or precipitins were detected in nine of them
(34.6%, data not shown), indicating chronic exposure. Overall,
the high sensitivity of PCR on sputum could contribute to more
effective grading of Aspergillus disease in CF patients together
with clinical signs and other biological markers, as proposed by
Baxter et al. (2013).
The optimal therapeutic management of CF patients
chronically colonized with Aspergillus is still a matter of debate.
There is no consensus on the use of triazole components
when A. fumigatus is detected in respiratory samples (Burgel
et al., 2016). However, the emergence of A. fumigatus strains
resistant to azole drugs has to be taken into account for clinical
management. Here we observed reduced susceptibility to
itraconazole in 5/41 A. fumigatus isolates (12.2%) similar to that
already reported (Morio et al., 2012). The growing incidence
of resistant fungi in clinical specimens is currently driving the
development of new molecular approaches for rapid resistance
screening directly on respiratory samples. As far as we know,
this study was the first prospective evaluation of commercial
multiplex PCRs to monitor triazole resistance in CF samples.
These assays did not enable us to detect any hotspot mutation
markers in the 57 and 64 sputum samples amplified with
Aspergenius R© Af PCR and Mycogenie R© PCR, respectively. It
should be noted that, in the respiratory samples from British
patients with CPA, high azole resistance rates was reported
using PCR (around 50%), while the cultures remained negative
(Denning et al., 2011).
Globally, the sensitivity of marketed cyp51A PCR assays
was low, primarily due to there being only a single copy of
the gene. In contrast, culture isolation of resistant Aspergillus
enabled us to sequence cyp51A. Of the five resistant isolates,
three displayed TR34/L98H, M220 or G54 mutations that have
already been linked to azole resistance in CF patients. Moreover,
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strains without any cyp51A alterations have been shown to
be an emerging concern, suggesting the possibility there are
other mechanisms responsible for triazole resistance (Rivero-
Menendez et al., 2016).
Finally, PCR achieved much higher positivity in its detection
of Aspergillus than culture, regardless of the method used
(in-house or marketed). As for multiplex PCR, also able to
detect cyp51A mutations, the presence of this gene in a
single copy limits the sensitivity of a molecular approach
compared to culture. There are, however, two potential
limits to the resistance screening method based on MIC
determination that should be discussed. Firstly, MIC is usually
determined using a single colony in routine practice, yet
there has been biodiversity reported within the same sputum.
For example, a previous study reported up to 28% of CF
patients presented complex colonization patterns containing
various genotypes which succeeded each other, regardless of
their antifungal susceptibility (de Valk et al., 2009). In our
study, of the five patients colonized with resistant strains,
only two produced several consecutive cultures growing with
resistant strains (patients 3 and 4, Figure 2), despite no drug
switches being performed between samplings. To overcome
this potential inaccuracy, the use of a selective medium
supplemented with antifungals for resistance detection from
primary culture is currently spreading in routine practice,
although there are no studies as yet reporting their relevance
in CF samples (Hamprecht et al., 2017). Secondly, while
there are few strains that show low MICs to itraconazole
and resistance to voriconazole, itraconazole should be the
preferred drug for measuring in vitro MIC due to the
discrepancies between resistance expression against the various
azoles. However, this procedure may miss some exceptional
strains resistant to voriconazole despite low itraconazole
MIC.
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